Foresite Capital Management V LLC Trims Stock Position in Lyell Immunopharma, Inc. $LYEL
Foresite Capital Management V LLC reduced its holdings in Lyell Immunopharma, Inc. by 95% in Q2, as per its latest SEC filing. The firm now owns 406,652 shares, down from 8.1 million, making Lyell its 6th largest holding. Institutional investors own 66.05% of Lyell's stock. Analysts have mixed ratings on the stock, with a consensus rating of "Reduce" and a target price of $20.00. Lyell's stock opened at $22.72, with a market cap of $482.12 million.
Foresite Capital Management V LLC trimmed its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 95.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 406,652 shares of the company's stock after selling 7,726,395 shares during the period. Lyell Immunopharma comprises about 4.5% of Foresite Capital Management V LLC's investment portfolio, making the stock its 6th largest holding. Foresite Capital Management V LLC owned about 2.63% of Lyell Immunopharma worth $3,595,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of the business. Almitas Capital LLC raised its position in shares of Lyell Immunopharma by 136.3% during the first quarter. Almitas Capital LLC now owns 2,482,606 shares of the company's stock worth $1,336,000 after purchasing an additional 1,432,086 shares during the period. Nuveen LLC bought a new stake in Lyell Immunopharma during the 1st quarter worth approximately $345,000. Acadian Asset Management LLC raised its holdings in Lyell Immunopharma by 204.2% during the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company's stock worth $354,000 after buying an additional 443,614 shares during the period. Finally, AQR Capital Management LLC lifted its stake in Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company's stock valued at $94,000 after buying an additional 154,327 shares in the last quarter. 66.05% of the stock is currently owned by institutional investors.
Get Lyell Immunopharma alerts:
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Lyell Immunopharma from a "sell" rating to a "hold" rating in a research report on Monday, September 1st. HC Wainwright reiterated a "neutral" rating and set a $20.00 target price (up previously from $10.00) on shares of Lyell Immunopharma in a report on Monday. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Lyell Immunopharma in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Lyell Immunopharma presently has a consensus rating of "Reduce" and a consensus price target of $20.00.
View Our Latest Report on Lyell Immunopharma
Lyell Immunopharma Price Performance
Shares of NASDAQ:LYEL opened at $22.72 on Tuesday. The company's 50-day moving average price is $16.54 and its two-hundred day moving average price is $12.41. Lyell Immunopharma, Inc. has a one year low of $7.65 and a one year high of $22.99. The stock has a market capitalization of $482.12 million, a PE ratio of -0.99 and a beta of -0.07.
Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.81) by $0.68. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%.The company had revenue of $0.02 million during the quarter, compared to analysts' expectations of $0.01 million. On average, analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.
Lyell Immunopharma Company Profile
(Free Report)Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
See Also
- Five stocks we like better than Lyell Immunopharma
- How to Calculate Return on Investment (ROI)
- D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?
- Financial Services Stocks Investing
- Hims, Block, and NRG Just Launched Huge Stock Buybacks
- What Are the U.K. Market Holidays? How to Invest and Trade
- Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Lyell Immunopharma Right Now?
Before you consider Lyell Immunopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.
While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
